aibio
Listings ·
Connect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule
The company's American Depositary Shares closed at $1.00 or more for 10 straight business days, ending a deficiency first flagged on March 24, 2025.
CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings (CNTB) news CNTB Nasdaq notice news
Latest Connect Biopharma Holdings news
We have not published a story on Connect Biopharma Holdings yet. When there is news, it will appear here.
What Connect Biopharma Holdings does
Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha (IL-4Rα). Rademikibart is a human monoclonal IgG4 antibody that inhibits both interleukin 4 and interleukin 13 signaling by blocking their shared receptor subunit. The company's focus is treatment of acute exacerbations of asthma and COPD. Two Phase 2 trials, Seabreeze STAT ASTHMA and Seabreeze STAT COPD, began in May 2025, and the company expects topline data from them in mid-2026. The FDA aligned on the design of these trials, which compare rademikibart plus standard of care with standard of care plus placebo. In March 2026 the company reported positive topline data from a Phase 1 clinical pharmacology study of intravenous rademikibart in patients with stable asthma or COPD. The text also describes a previously completed global Phase 2b chronic asthma study, CBP-201-WW002, which the company says supports its current development plan.
| Product or program | What it is | Stage |
|---|---|---|
| Rademikibart (acute asthma) | IL-4Rα antibody for acute exacerbations of asthma | Phase 2 |
| Rademikibart (acute COPD) | IL-4Rα antibody for acute exacerbations of COPD | Phase 2 |
| Rademikibart (chronic asthma) | IL-4Rα antibody tested in a global chronic asthma trial, CBP-201-WW002 | Phase 2b, completed |
| Rademikibart (IV) | Intravenous formulation tested in stable asthma and COPD patients | Phase 1, positive topline data March 2026 |
Connect Biopharma Holdings annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $64,000 | $26.0 million |
| Research and development | $37.8 million | $29.3 million |
| Net income (loss) | -$55.5 million | -$15.6 million |
| Cash from operations | -$51.2 million | -$23.6 million |
| Cash and equivalents | $38.3 million | $78.2 million |
| Short-term investments | $6.0 million | $15.5 million |
Questions about Connect Biopharma Holdings
Has Connect Biopharma Holdings received a Nasdaq deficiency notice?
Our latest story on this, dated Jul 17, 2025: "Connect Biopharma regains compliance with Nasdaq $1.00 minimum bid price rule". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Connect Biopharma Holdings?
Connect Biopharma Holdings Limited trades under the ticker CNTB on NASDAQ.
Where is Connect Biopharma Holdings listed?
Connect Biopharma Holdings Limited is listed on NASDAQ.
What is the SEC CIK of Connect Biopharma Holdings?
The SEC Central Index Key (CIK) for Connect Biopharma Holdings Limited is 1835268. Its filings are on SEC EDGAR.
How many shares does Connect Biopharma Holdings have outstanding?
62,974,309 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Connect Biopharma Holdings listed under?
Our directory records Connect Biopharma Holdings Limited under United States.
What does Connect Biopharma Holdings do?
Our directory classifies Connect Biopharma Holdings Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Connect Biopharma Holdings?
The ISIN recorded for Connect Biopharma Holdings Limited is KYG235491019.
Does aibio.space cover Connect Biopharma Holdings?
aibio.space lists Connect Biopharma Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Connect Biopharma Holdings incorporated?
SEC records list its state or country of incorporation as E9.
What does Connect Biopharma Holdings develop?
Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha (IL-4Rα).
What is Rademikibart (acute asthma) from Connect Biopharma Holdings?
Rademikibart (acute asthma): IL-4Rα antibody for acute exacerbations of asthma Stage: Phase 2.
What is Rademikibart (acute COPD) from Connect Biopharma Holdings?
Rademikibart (acute COPD): IL-4Rα antibody for acute exacerbations of COPD Stage: Phase 2.
What was Connect Biopharma Holdings's revenue last year?
$64,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Connect Biopharma Holdings profitable?
Connect Biopharma Holdings Limited reported a net loss of $55.5 million for the fiscal year ended Dec 31, 2025, and used $51.2 million of cash in operations, per its annual report to the SEC.
Investor discussion: Connect Biopharma Holdings
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Stock chart
SEC filings and registration
- SEC name
- Connect Biopharma Holdings Ltd
- CIK
- 1835268
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- CNTB (Nasdaq)
- State or country of incorporation
- E9
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, 92130
- Phone
- 858-727-1040
- Shares outstanding
- 62,974,309 as of 2026-07-31 (10-Q filed 2026-08-12)
Recent filings
Listing details
- Company
- Connect Biopharma Holdings Limited
- Ticker
- CNTB
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- KYG235491019
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction